Other
State
Vertex Pharmaceuticals State remained flat by 0.0% to -$5.53M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 54.6%, from -$12.18M to -$5.53M. Over 2 years (FY 2023 to FY 2025), State shows relatively stable performance with a 0.5% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
An increase in deferred tax assets suggests future tax benefits, while an increase in deferred tax liabilities suggests future tax payments.
Detailed definition
Represents the portion of state and local income tax expense that is deferred to future periods due to temporary differe...
Peer comparison
Commonly reported by large U.S. corporations with multi-state operations; peers typically disclose this in the tax footnote.
Metric ID:
other_deferred_state_and_local_income_tax_expense_benefitHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$21.90M | -$48.70M | -$22.10M |
| YoY Change | — | -122.4% | +54.6% |
Range-$48.70M – -$21.90M
CAGR+0.5%
Avg YoY Growth-33.9%
Median YoY Growth-33.9%
State at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's state?
- Vertex Pharmaceuticals (VRTX) reported state of -$5.53M in Q4 2025.
- How has Vertex Pharmaceuticals's state changed year-over-year?
- Vertex Pharmaceuticals's state increased by 54.6% year-over-year, from -$12.18M to -$5.53M.
- What is the long-term trend for Vertex Pharmaceuticals's state?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's state has grown at a 0.5% compound annual growth rate (CAGR), from -$21.90M to -$22.10M.
- What does state mean?
- The portion of state and local income taxes that will be paid or realized in future periods.